Cancer Information

Atossa Genetics, The Breast Health Company

Dr. Steven C. Quay, M.D., Ph.D., is Chief Executive Officer and Chairman of the Board of Directors of Atossa Genetics, The Breast Health Company™ and joins eHealth Radio and the Cancer Prevention Channel. Dr. Quay has a total of 75 U.S. patents, 98 pending patent applications and is a named inventor on patents covering five pharmaceutical products that have been approved by the FDA.
Listen to interview [audio player below] with host Eric Michaels & guest Dr. Steven Quay discuss the following:
What led you to dedicate yourself to your area of research and/or practice?
What new approaches to breast health is Atossa Genetics taking?
What treatments or interventions are available if Atossa testing identifies an elevated risk of breast cancer?
How does the cost for Atossa testing compare with mammograms and is it covered by insurance?
How do patients find a provider for Atossa testing?
What tip would you give to women to maintain their breast health?


Dr. Quay has served as Chief Executive Officer and Chairman of the Board of Atossa Genetics, Inc.  since the Company was incorporated in April 2009. Atossa is focused on preventing breast cancer through the commercialization of patented, FDA-cleared diagnostic medical devices and patented, laboratory developed tests (LDT) that can detect precursors to breast cancer up to eight years before mammography, and through research and development that will permit it to commercialize treatments for pre-cancerous lesions.
Atossa Genetics, headquartered in Seattle, has developed and markets a hand held, FDA-cleared, clinically proven and peer-reviewed “Pap smear for the breast” for early detection of cancerous cells or pre-cancerous conditions non-invasively, in the physician’s office.  Atossa’s ForeCYTE Breast Health Test can provide vital early-detection of cancerous or pre-cancerous conditions years before they can be detected by other means and without risks of radiation, especially in women younger than 50.
Prior to his work at Atossa, Dr. Quay served as Chairman of the Board, President and Chief Executive Officer of MDRNA, Inc. from August 2000 to May 2008, and as its Chief Scientific Officer until November 30, 2008 (MDRNA, Inc. was formerly known as Nastech Pharmaceutical Company Inc. and is currently known as Marina Biotech, Inc.). From December 2008 to April 2009, Dr. Quay was involved in acquiring the Company's assets and preparing the Company's business plan. Dr. Quay is certified in Anatomic Pathology with the American Board of Pathology, completed both an internship and residency in anatomic pathology at the Massachusetts General Hospital, a Harvard Medical School teaching hospital, is a former faculty member of the Department of Pathology, Stanford University School of Medicine, and is a named inventor on 14 U.S. and foreign patents covering the MASCT System.
Dr. Quay oversaw the clinical testing and regulatory filing of the MASCT device with the FDA that led to its ultimate marketing clearance. Including the patents for the MASCT System, Dr. Quay has a total of 75 U.S. patents, 98 pending patent applications and is a named inventor on patents covering five pharmaceutical products that have been approved by the FDA. Dr. Quay received an M.D. in 1977 and a Ph.D. in 1975 from the University of Michigan Medical School. He also received his B.A. degree in biology, chemistry and mathematics from Western Michigan University in 1971. Dr. Quay is a member of the American Society of Investigative Pathology, the Association of Molecular Pathology, the Society for Laboratory Automation and Screening and the Association of Pathology Informatics.

Related Web Site: www.atossagenetics.com

Breast Left Unsaid by Jude Callirgos

Jude Callirgos is the author of Breast Left Unsaid about her current battle with breast cancer and joins eHealth Radio and the Cancer Prevention and Cancer Information Channels.
Listen to interview [audio player below] with host Eric Michaels & guest Jude Callirgos discuss the following:
Tell us about your book, why did you write it?
What will readers learn?
Who would want to read this book?
Several reviews of Breast Left Unsaid note that the book is very funny; how did you manage that considering the subject matter?
You're still fighting this disease, so what are the key things you do for yourself to support your own health / what advice do you have for our listeners who are fighting cancer or know someone who is?


Jude Callirgos lives in Connecticut with her husband Philip, dog Sophie, and assorted woodland creatures. She is also a wicked step-mom to daughter Julia, enjoying college in Vermont. Despite her ongoing fight with advanced breast cancer, Jude intends to continue writing, blogging and advocating on this and other topics for a long time to come. Breast Left Unsaid is her first full-length book. She invites you to visit her website at www.breastleftunsaid.com, and looks forward to your feedback. Jude also thanks you for buying her book "Breast Left Unsaid" and wants you to know that a percentage of the proceeds will go toward medical research focused on a cure for breast cancer and other diseases affecting her family.

Related Web Site: www.breastleftunsaid.com

Beljanski Foundation, Cancer’s Cause and Cancer’s Cure

Dr. John Hall and Sylvie Beljanski speak about the background and history associated with Mirko Beljanski, the development of the Beljanski Foundation and the research being done at the University of Kansas Medical Center and the study’s findings associated with ovarian, prostate and pancreatic cancers. Additionally, they also discuss Morton Walker’s recent book published about Dr. Beljanski’s research called Cancer’s Cause and Cancer’s Cure.
Listen to interview [audio player below] with host Eric Michaels & guests Dr. John Hall and Sylvie Beljanski discuss the following:
What is the mission of the Beljanski Foundation?
Who is Mirko Beljanski and what did he discover?
What are the latest findings/studies being conducted by the Beljanski Foundation?
Sylvie, as the daughter of the late Mirko Beljanski, what is your vision for the Foundation?
Where can one find more information about the work of Mirko Beljanski and the Beljanski Foundation?


Sylvie Bejanski, Vice President Beljanski Foundation
Sylvie Beljanski is committed to continuing the Beljanski family legacy as international leaders in environmental medicine research. Through the work of her father, Mirko Beljanski, Ph.D., and the ongoing research currently being conducted, Ms. Beljanski believes that there is more to be found in alternative medicine and its benefits to those who are fighting life threatening diseases. Born in New York City and raised and educated in Paris, Sylvie Beljanski completed her undergraduate studies at The Sorbonne. She then went on to pursue a law degree and was admitted to the French Bar in 1995. After her father’s passing in 1998, Ms. Beljanski immediately became committed to spreading the word and educating the public about Dr. Beljanski’s discoveries. Traveling throughout the world, she’s educated tens of thousands of people about the importance of detoxification as a defense against harmful toxins that can cause serious disease and infection. She presents The Beljanski® Approach to Wellness with practical recommendations to avoid environmental toxins, remove them and repair the cellular process.
In 1999, Ms. Beljanski became the Vice-President of The Beljanski Foundation, Inc., a 501(c)3 charitable organization whose mission is to further Dr. Beljanski’s research within a network of high-profile research institutions around the world. Her dedication to spreading the word beyond Europe, where it originated, and the U.S., most recently brought her to speak at the General Practitioner Conference & Exhibition in Australia, where they largely accepted these ideas and practices and were eager to join in on the conversation. Ms. Beljanski keeps track of her travels and speaking engagements on her well-followed blog, www.thebeljanskiblog.com.
Ms. Beljanski and The Beljanski Foundation are continuing Mirko Beljanski’s legacy by funding new studies by Columbia University that are seeing the success of botanical extracts Dr. Beljanski discovered in suppressing tumors, including prostate tumors, without damaging healthy cells. They are confident that similar breakthrough discoveries are soon to be revealed about pancreatic and ovarian cancer cells as well.
In addition, new studies by the University of Kansas Medical Center are pointing to the efficacy of two powerful botanical extracts that have shown successful in destroying cancer cells that have resisted chemotherapy. The extracts are believed to promote ovarian health and be a low-toxicity alternative to highly toxic chemo drugs.
-----------
John Hall, Ph.D.
As the Senior Scientific Advisor of The Beljanski Foundation, John Hall, Ph.D. presents at scientific conferences and at universities all over the United States and in Europe. Dr. Hall is published in major journals including Cell, Proceedings of the National Academy, Journal of Cell Biology, Molecular and Cell Biology, and Genetics.
Dr. Hall completed his graduate work in biochemistry at Princeton University and New York University. As a post-doctoral fellow and then as a professor at Rockefeller University, his research focused on the fundamental mechanisms relating cell motility to cell division and cancer. He has served as an executive and as a consultant in the biotechnology industry.
Born and raised in Princeton, New Jersey, Dr. Hall feels privileged and honored to continue the work started by the late Mirko Beljanski, Ph.D., and is dedicated to spreading his work and broadening his research through the Beljanski Foundation.
Related Web Site: www.beljanski.com